A Single-institutional Analysis of Racial Disparities in Clinicopathologic Characteristics, Treatment Selections, and Outcomes in Advanced-stage Pancreatic Cancer Patients

Overview

Journal Ann Pancreat Cancer

Publisher AME Publishing Company

Date 2021 Dec 29

PMID 34964042

Authors

Matthew Williams

Umut Ozbek

Jung-Yi Lin

Celina Ang

Affiliations

Soon will be listed here.

Abstract

Background: To investigate racial disparities among unresectable/metastatic pancreatic ductal adenocarcinoma (PDA) patients treated with contemporary chemotherapy regimens at an urban center.

Methods: Retrospective review of all PDA patients treated at a single institution between 2012-2017. Continuous and categorical variables were tested using -test, Mann-Whitney U, chi-squared or Fisher's exact test as appropriate. Kaplan-Meier curves were generated and Cox proportional hazards models were used to analyze survival outcomes.

Results: One hundred and forty-five patients identified as: White [69], African American (AA, 34), Asian [15], and Other [27]. Fifty-five-point-seven percent of patients received gemcitabine-based therapy 36.6% received fluorouracil (5-FU) based therapy, specifically 26.1% received FOLFIRINOX and 43.7% received gemcitabine/nab-paclitaxel. In a univariable model, Asians had significantly worse overall survival (OS) than Whites [hazard ratio (HR) 2.74, P=0.013], but there were no OS differences between AA Whites (HR 1.51, P=0.297) nor Other Whites (HR 2.05, P=0.062). On multivariable analysis, Asians had worse OS compared to Whites (HR 2.62, P=0.018), and gemcitabine-based therapy was inferior to 5-FU-based therapy (HR 2.65, P=0.005). There were no OS differences between AA . Whites nor Other . Whites (HR 1.12, P=0.769 and HR 0.8, P=0.763, respectively).

Conclusions: In this series of advanced PDA patients treated with contemporary chemotherapy, AA and White patients had comparable outcomes, but Asians had worse OS than White patients.

References

Silverman D, Hoover R, Brown L, Swanson G, Schiffman M, Greenberg R . Why do Black Americans have a higher risk of pancreatic cancer than White Americans?. Epidemiology. 2002; 14(1):45-54. DOI: 10.1097/00001648-200301000-00013. View

Tohme S, Kaltenmeier C, Bou-Samra P, Varley P, Tsung A . Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Pancreatic Cancer: An NCDB Cohort Study. Ann Surg Oncol. 2018; 25(12):3427-3435. DOI: 10.1245/s10434-018-6680-6. View

Longnecker D, Karagas M, Tosteson T, Mott L . Racial differences in pancreatic cancer: comparison of survival and histologic types of pancreatic carcinoma in Asians, blacks, and whites in the United States. Pancreas. 2000; 21(4):338-43. DOI: 10.1097/00006676-200011000-00003. View

Arnold L, Patel A, Yan Y, Jacobs E, Thun M, Calle E . Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity?. Cancer Epidemiol Biomarkers Prev. 2009; 18(9):2397-405. PMC: 3630792. DOI: 10.1158/1055-9965.EPI-09-0080. View

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

Nipp R, Tramontano A, Kong C, Pandharipande P, Dowling E, Schrag D . Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med. 2018; 7(2):525-535. PMC: 5806100. DOI: 10.1002/cam4.1277. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Kittles R, Weiss K . Race, ancestry, and genes: implications for defining disease risk. Annu Rev Genomics Hum Genet. 2003; 4:33-67. DOI: 10.1146/annurev.genom.4.070802.110356. View

Woods L, Rachet B, Coleman M . Origins of socio-economic inequalities in cancer survival: a review. Ann Oncol. 2005; 17(1):5-19. DOI: 10.1093/annonc/mdj007. View

10.

Von Hoff D, Ervin T, Arena F, Chiorean E, Infante J, Moore M . Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18):1691-703. PMC: 4631139. DOI: 10.1056/NEJMoa1304369. View

11.

Wu Y, Lu Z, Zhang J, Liu D, Shi G, Zhang C . Association between ERCC2 Lys751Gln polymorphism and the risk of pancreatic cancer, especially among Asians: evidence from a meta-analysis. Oncotarget. 2017; 8(30):50124-50132. PMC: 5564835. DOI: 10.18632/oncotarget.15394. View

12.

Abraham A, Al-Refaie W, Parsons H, Dudeja V, Vickers S, Habermann E . Disparities in pancreas cancer care. Ann Surg Oncol. 2013; 20(6):2078-87. DOI: 10.1245/s10434-012-2843-z. View

13.

Wray C, Castro-Echeverry E, Silberfein E, Ko T, Kao L . A multi-institutional study of pancreatic cancer in Harris County, Texas: race predicts treatment and survival. Ann Surg Oncol. 2012; 19(9):2776-81. DOI: 10.1245/s10434-012-2361-z. View

14.

Pernick N, Sarkar F, Philip P, Arlauskas P, Shields A, Vaitkevicius V . Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians. Pancreas. 2002; 26(1):28-32. DOI: 10.1097/00006676-200301000-00006. View

15.

Singal V, Singal A, Kuo Y . Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis. J Cancer Res Clin Oncol. 2012; 138(4):715-22. DOI: 10.1007/s00432-012-1156-8. View

16.

Khawja S, Mohammed S, Silberfein E, Musher B, Fisher W, Van Buren 2nd G . Pancreatic cancer disparities in African Americans. Pancreas. 2015; 44(4):522-7. DOI: 10.1097/MPA.0000000000000323. View

17.

Heller D, Nicolson N, Ahuja N, Khan S, Kunstman J . Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surg. 2019; 155(2):e195047. PMC: 6902102. DOI: 10.1001/jamasurg.2019.5047. View

18.

Dong M, Nio Y, Tamura K, Song M, Guo K, Guo R . Ki-ras point mutation and p53 expression in human pancreatic cancer: a comparative study among Chinese, Japanese, and Western patients. Cancer Epidemiol Biomarkers Prev. 2000; 9(3):279-84. View

19.

Fitzgerald T, Bradley C, Dahman B, Zervos E . Gastrointestinal malignancies: when does race matter?. J Am Coll Surg. 2009; 209(5):645-52. DOI: 10.1016/j.jamcollsurg.2009.08.007. View